Comparative Pharmacology
Head-to-head clinical analysis: CORTIFOAM versus DEXACEN 4.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORTIFOAM versus DEXACEN 4.
CORTIFOAM vs DEXACEN-4
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cortifoam (hydrocortisone acetate) is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to induce anti-inflammatory, antipruritic, and vasoconstrictive effects. It inhibits phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppresses immune cell migration and cytokine release.
Dexamethasone is a glucocorticoid receptor agonist that binds to the glucocorticoid receptor, leading to increased transcription of anti-inflammatory proteins and suppression of pro-inflammatory mediators.
1 applicatorful (90 mg hydrocortisone acetate) rectally twice daily for 2-3 weeks, then every other day as needed.
Dexamethasone 4 mg orally or intravenously every 6-8 hours; typical adult dose is 4-20 mg/day in divided doses, depending on condition.
None Documented
None Documented
Approximately 1.5-2 hours for hydrocortisone; clinically, effects persist longer due to local action.
3-4 hours; prolonged to 6-8 hours in renal impairment (CrCl <30 mL/min)
Primarily renal (about 70-90% as metabolites) and fecal (about 10-30% as metabolites).
Renal: 65-80% as unchanged drug; Biliary: 10-15% as metabolites; Fecal: <5%
Category C
Category C
Corticosteroid
Corticosteroid